Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Daratumumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Treated in an Italian Real-Life Multi-Center Retrospecive Study

Rosario Bianco, Roberta Della Pepa, Aldo Leone, Raffaele Fontana, Stefano Rocco, Angela Amendola, Salvatore Palmieri, Daniela Esposito, Daniela Roccotelli, Giuseppe Delle Cave, Maria Rosaria Spatuzzi, Roberta Spisso, Claudio Cerchione, Marialucia Barone, Cirino Botta, Daniele Derudas, Carmine Selleri, Ferdinando Frigeri

Blood (2024) 144 (Supplement 1): 7876.

https://doi.org/10.1182/blood-2024-210058

Published: 2024

Journal Articles

Treatment of Chronic ITP with Avatrombopag: A Multicentric Real-World Experience

Mario Troiano, Claudia Giordano, Elena Rossi, Potito Rosario Scalzulli, Laura Mettivier, Alessandro D'Ambrosio, Daniele Mazzoni, Erika Vatiero, Carmine Selleri, Fabrizio Pane, Ferdinando Frigeri

Blood (2024) 144 (Supplement 1): 5446.

https://doi.org/10.1182/blood-2024-210230

Published: 2024

Journal Articles

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence

Blood (2022) 140 (Supplement 1): 4178–4180.

https://doi.org/10.1182/blood-2022-166140

Published: 2022

Journal Articles

The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report

Blood (2021) 138 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2021-148378

Published: 2021

Journal Articles

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Blood (2018) 132 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2018-99-115340

Published: 2018

Journal Articles

Dendritic Cells Subsets Profiles in Classical Hodgkin Lymphoma at Diagnosis and upon Treatment Completion: Analysis on 54 Patients

Domenico Galati, MD PhD, Serena Zanotta, ScD, Gaetano Corazzelli, MD, Bruzzese Dario, PhD, Gaetana Capobianco, MD, Emanuela Morelli, MD, Manuela Arcamone, MD, Ferdinando Frigeri, MD, Rosaria De Filippi, MD PhD, Antonio Pinto, MD

Blood (2017) 130 (Supplement 1): 4095.

https://doi.org/10.1182/blood.V130.Suppl_1.4095.4095

Published: 2017

Journal Articles

Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance

Rosaria De Filippi, MD PhD, Stefania Crisci, ScD, Sara Mele, BS, Serena Zanotta, ScD, Gaetano Corazzelli, MD, Domenico Galati, MD PhD, Davide Coppola, RN, Piera Maiolino, PharmD, Mariangela Saggese, PharmD, Francesco Volzone, MD, Emanuela Morelli, MD, Daniela Donnarumma, MD, Gianpaolo Marcacci, MD, Ferdinando Frigeri, MD, Niels Odum, MD, Thomas Mehrling, MD PhD, Antonio Pinto, MD

Blood (2017) 130 (Supplement 1): 2547.

https://doi.org/10.1182/blood.V130.Suppl_1.2547.2547

Published: 2017

Journal Articles

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Kristina Lerch, Corinna Leng, Antonello Pinto, Werner Linkesch, Heinz Sill, Ola Linden, Andreas Viardot, Ulrich Keller, Georg Hess, MD, Secondo Lastoria, Ferdinando Frigeri, Nicole Neik, Christiane Pott, Christian W. Scholz, Antonio Pezzutto, MD PhD

Blood (2016) 128 (22): 1806.

https://doi.org/10.1182/blood.V128.22.1806.1806

Published: 2016

Journal Articles

Continuous Exposure to Bendamustine (BDM) Results in Stable Upregulation of CD30 and Increased Sensitivity to Brentuximab Vedotin (BV) in Tumor Cells of Hodgkin Lymphoma (HL)

Rosaria De Filippi, MD PhD, Michele Cillo, ScD, Stefania Crisci, ScD, Sara Mele, BS, Serena Zanotta, ScD, Angela De Monaco, ScD, Domenico Galati, MD, Giancarla Iaccarino, ScD, Raffaele Di Francia, ScD, Emanuela Morelli, MD, Gianpaolo Marcacci, MD, Cristina Becchimanzi, MD, Attilio Guarini, MD, Ferdinando Frigeri, MD PhD, Gaetano Corazzelli, MD, Antonello Pinto, MD

Blood (2015) 126 (23): 2479.

https://doi.org/10.1182/blood.V126.23.2479.2479

Published: 2015

Journal Articles

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Rosaria De Filippi, MD PhD, Stefania Crisci, ScD, Michele Cillo, ScD, Sara Mele, BS, Angela De Monaco, ScD, Domenico Galati, MD, Serena Zanotta, ScD, Gaetana Capobianco, MD, Francesco Volzone, MD, Manuela Arcamone, MD, Piera Maiolino, PharmD, Mariangela Saggese, PharmD, Gaetano Corazzelli, MD, Ferdinando Frigeri, MD PhD, Thomas Mehrling, MD PhD, Antonello Pinto, MD

Blood (2015) 126 (23): 2481.

https://doi.org/10.1182/blood.V126.23.2481.2481

Published: 2015

Journal Articles

Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

Antonello Pinto, MD, Vincenzo Pavone, MD, Francesco Angrilli, MD, Mariangela Saggese, PharmD, Stefania Crisci, ScD, Caterina Patti, MD, Pier Luigi Zinzani, MD PhD, Alfonso Maria D'Arco, MD, Elena Cavalieri, MD, Attilio Guarini, MD, Michele Spina, MD, Daniela Carlino, MD, Simona Falorio, MD, Emanuela Morelli, MD, Manuela Arcamone, MD, Ferdinando Frigeri, MD PhD, Annarosaria De Chiara, MD, Rosaria De Filippi, MD PhD, Gaetano Corazzelli, MD

Blood (2015) 126 (23): 1541.

https://doi.org/10.1182/blood.V126.23.1541.1541

Published: 2015

Journal Articles

Molecular Determinants of Bendamustine (BDM) Toxicity towards Hodgkin (H) and Reed-Sternberg (RS) Cell Lines From Hodgkin Lymphoma (HL).

Rosaria De Filippi, MD, PhD, Stefania Crisci, PhD, Ferdinando Frigeri, MD, PhD, Donatella Aldinucci, PhD, Domenico Galati, MD, Rosa Calemma, PhD, Giulio Abagnale, PhD, Gaetana Capobianco, MD, Manuela Arcamone, MD, Raffaele Di Francia, DPharm, Laura Mettivier, MD, Mariangela Saggese, PhD, Gaetano Corazzelli, MD, Antonio Pinto, MD

Blood (2012) 120 (21): 2763.

https://doi.org/10.1182/blood.V120.21.2763.2763

Published: 2012

Journal Articles

Peptide Nucleic Acid (PNA)-Clamping Competitive PCR: A New Tool for the High Sensitive Detection of JAK2V617F Mutation in Myeloproliferative Neoplasms (MPNs)

Ferdinando Frigeri, MD, PhD, Raffaele Di Francia, PhD, Luigi Petraccone, PhD, Concetta Giancola, PhD, Annunziata Cummaro, PhD, Paolo Danise, MD, Stefania Crisci, PhD, Giancarla Iaccarino, PhD, Rosaria De Filippi, MD, PhD, Emanuela Morelli, MD, Gaetana Capobianco, MD, Francesco Volzone, MD, Alfonso Maria D'Arco, MD, Antonio Pinto, MD

Blood (2011) 118 (21): 5168.

https://doi.org/10.1182/blood.V118.21.5168.5168

Published: 2011

Journal Articles

90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

Christian W. Scholz, MD, Antonello Pinto, MD, Werner Linkesch, MD, Ola Linden, MD, Andreas Viardot, MD, Ulrich Keller, MD, Georg Hess, MD, Kristina Lerch, MD, Ferdinando Frigeri, MD, Manuela Arcamone, MD, Bernd Frericks, MD, Christiane Pott, MD, Antonio Pezzutto

Blood (2010) 116 (21): 593.

https://doi.org/10.1182/blood.V116.21.593.593

Published: 2010

Journal Articles

Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.

Gaetano Corazzelli, MD, Ferdinando Frigeri, MD, Gianpaolo Marcacci, MD, Cristina Becchimanzi, MD, Gaetana Capobianco, MD, Manuela Arcamone, MD, Emanuela Morelli, MD, Francesco Volzone, MD, Filippo Russo, MD, Antonio Pinto, MD

Blood (2010) 116 (21): 2829.

https://doi.org/10.1182/blood.V116.21.2829.2829

Published: 2010

Journal Articles

Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease.

Ferdinando Frigeri, MD, Gaetano Corazzelli, MD, Manuela Arcamone, MD, Gaetana Capobianco, MD, Anna Lucania, MD, Cristina Becchimanzi, MD, Gianpaolo Marcacci, MD, Filippo Russo, MD, Maria Rosaria Villa, MD, Lucia Mastrullo, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 1664.

https://doi.org/10.1182/blood.V114.22.1664.1664

Published: 2009

Journal Articles

Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.

Filippo Russo, MD, Gaetano Corazzelli, MD, Secondo Lastoria, MD, Gianpaolo Marcacci, MD, Ferdinando Frigeri, MD, Gaetana Capobianco, Cristina Becchimanzi, MD, Manuela Arcamone, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 715.

https://doi.org/10.1182/blood.V114.22.715.715

Published: 2009

Journal Articles

Abnormally Elevated Levels of Serum Free-Immunoglobulin Light Chains Are Frequently Found in Classic Hodgkin Lymphoma (cHL) and Predict Outcome of Patients with Early Stage Disease.

Rosaria De Filippi, MD, PhD, Filippo Russo, MD, Giancarla Iaccarino, D.Sci, Stefania Crisci, D.Sci, Ferdinando Frigeri, Costantino Riemma, Alessandro Marchei, D.Sci, Rosa Calemma, D.Sci, Raffaele Di Francia, D.Pharm, Gianpaolo Marcacci, MD, Gaetano Corazzelli, MD, Gaetana Capobianco, MD, Cristina Becchimanzi, MD, Manuela Arcamone, MD, Barbara Amoroso, MD, Giuseppe Castello, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 267.

https://doi.org/10.1182/blood.V114.22.267.267

Published: 2009

Journal Articles

Safety and Efficacy of Intrathecal Liposome-Encapsulated Cytarabine for Central Nervous System (CNS) Prophylaxis in Adult Patients with Burkitt and Atypical Burkitt Lymphoma Treated with the R-CODOX-M/R-IVAC (Magrath) Regimen: Results of a Phase II Study.

Ferdinando Frigeri, MD, Filippo Russo, MD, Manuela Arcamone, MD, Chiara Fraira, MD, Gennaro Russo, MD, Gaetana Capobianco, MD, Cristina Becchimanzi, MD, Arturo Cuomo, MD, Gianpaolo Marcacci, MD, Gennaro Esposito, MD, Rosaria De Filippi, MD, PhD, Gaetano Corazzelli, MD, Umberto Vitolo, MD, Antonio Pinto, MD

Blood (2009) 114 (22): 3716.

https://doi.org/10.1182/blood.V114.22.3716.3716

Published: 2009

Journal Articles

Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome–positive leukemia

Ferdinando Frigeri, Manuela Arcamone, Luigia Luciano, Raffaele Di Francia, Fabrizio Pane, Antonio Pinto

Blood (2009) 113 (20): 5028–5029.

https://doi.org/10.1182/blood-2008-11-191080

Published: 2009

NARROW

Efficacy and Safety of Daratumumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Treated in an Italian Real-Life Multi-Center Retrospecive Study

Treatment of Chronic ITP with Avatrombopag: A Multicentric Real-World Experience

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence

The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Dendritic Cells Subsets Profiles in Classical Hodgkin Lymphoma at Diagnosis and upon Treatment Completion: Analysis on 54 Patients

Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Continuous Exposure to Bendamustine (BDM) Results in Stable Upregulation of CD30 and Increased Sensitivity to Brentuximab Vedotin (BV) in Tumor Cells of Hodgkin Lymphoma (HL)

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

Molecular Determinants of Bendamustine (BDM) Toxicity towards Hodgkin (H) and Reed-Sternberg (RS) Cell Lines From Hodgkin Lymphoma (HL).

Peptide Nucleic Acid (PNA)-Clamping Competitive PCR: A New Tool for the High Sensitive Detection of JAK2V617F Mutation in Myeloproliferative Neoplasms (MPNs)

90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.

Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease.

Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.

Abnormally Elevated Levels of Serum Free-Immunoglobulin Light Chains Are Frequently Found in Classic Hodgkin Lymphoma (cHL) and Predict Outcome of Patients with Early Stage Disease.

Safety and Efficacy of Intrathecal Liposome-Encapsulated Cytarabine for Central Nervous System (CNS) Prophylaxis in Adult Patients with Burkitt and Atypical Burkitt Lymphoma Treated with the R-CODOX-M/R-IVAC (Magrath) Regimen: Results of a Phase II Study.

Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome–positive leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only